Mitochondrial-derived peptides: a class, not a product line
MOTS-c, humanin and related micropeptides are a real research field. Most human evidence is still association or early trials.
Mitochondrial DNA can encode short mitochondrial-derived peptides (MDPs) such as MOTS-c and humanin. They are studied as stress signals that may change metabolism, inflammation and cell survival in experimental systems.
What is new in 2025–2026
MOTS-c now has a registered Phase 2a insulin-sensitivity trial. That is class-level progress: at least one MDP is being tested as a drug candidate. It is not proof that the whole class works, and it is not a result.
Humanin
Humanin literature is still largely cellular, animal, or observational (circulating levels versus disease). That can generate hypotheses about aging biology. It does not justify unregulated “humanin” products.
Bottom line
Evidence ladder: Animal, with human trials beginning for MOTS-c. Keep the class together in reviews; split it apart when someone claims a vial will mimic exercise or reverse aging.
Sources
Educational content only — not medical advice. See our Medical disclaimer and Editorial policy.